This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Czuczman MS, Trněný M, Davies A, Rule S, Linton KM, Wagner-Johnston N, et al. A phase 2/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator’s choice in patients with relapsed or refractory diffuse large B-cell lymphoma. Clin Cancer Res. 2017;23:4127–37. https://doi.org/10.1158/1078-0432.CCR-16-2818.
Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Ann Oncol. 2011;22:1622–7.
Trněný M, Lamy T, Walewski J, Belada D, Mayer J, Radford J, et al. Lenalidomide versus investigator’s choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. Lancet Oncol. 2016;17:319–31. https://doi.org/10.1016/S1470-2045(15)00559-8.
Arcaini L, Lamy T, Walewski J, Belada D, Mayer J, Radford J, et al. Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator’s choice in relapsed or refractory mantle cell lymphoma. Br J Haematol. 2018;180:224–35. https://doi.org/10.1111/bjh.15025.
Morschhauser FA, Cartron G, Thieblemont C, Solal-Céligny P, Haioun C, Bouabdallah R, et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013;31:2912–9.
Leonard JP, Jung S-H, Johnson J, Pitcher BN, Bartlett NL, Blum KA, et al. Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance). J Clin Oncol. 2015;33:3635–40.
Martin P, Jung S-H, Pitcher B, Bartlett NL, Blum KA, Shea T, et al. A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin’s lymphoma (NHL): CALGB 50803 (Alliance). Ann Oncol J Eur Soc Med Oncol. 2017;28:2806–12.
Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol. 2012. https://doi.org/10.1016/S1470-2045(12)70200-0.
Ruan J, Martin P, Shah B, Schuster SJ, Smith SM, Furman RR, et al. Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma. N Engl J Med. 2015;373:1835–44.
Zinzani PL, Pellegrini C, Gandolfi L, Stefoni V, Quirini F, Derenzini E, et al. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk. 2011. https://doi.org/10.1016/j.clml.2011.02.001.
Ivanov V, Coso D, Chetaille B, Esterni B, Olive D, Aurran-Schleinitz T, et al. Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma. Leuk Lymphoma 2014. https://doi.org/10.3109/10428194.2014.889822.
Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. 2013. https://doi.org/10.1038/leu.2013.95.
Zinzani PL, Pellegrini C, Argnani L, Broccoli A. Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab. Haematologica. 2016;101:e385–6.
Morschhauser F, Salles G, Le Gouill S, Tilly H, Thieblemont C, Bouabdallah K, et al. An open-label, phase Ib study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma. Blood. 2018. https://doi.org/10.1182/blood-2018-05-853499.
Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. J Clin Oncol. PMID: 10561185. https://doi.org/10.1200/JCO.1999.17.4.1244.
Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130:1800–8.
Vitolo U, Trněný M, Belada D, Burke JM, Carella AM, Chua N, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol. 2017;35:3529–37. JCO.2017.73.340.
Acknowledgements
We thank the patients and their families; the Lymphoma Academic Research Organization team for the management of the study, in particular Elise Gaire and Clémentine Joubert; the reviewers at the Lymphoma Study Association (LYSA) notably Luc Xerri, Peggy Dartigues, Bettina Fabiani, Danielle Canioni, Catherine Chassagne-Clement, Camille Laurent, Véronique Meignin; the Independent Data Monitoring Committee (André Bosly, Catherine Sebban, and Natacha Heutte); and all the investigators. Funding support and drug supply were provided by F. Hoffmann La Roche Ltd and Celgene Corporation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
RH: Honoraria: Bristol-Myers Squibb, Novartis, Janssen, Celgene, Consultant: Bristol-Myers Squibb; GC: Honoraria: Sanofi, Gilead, Janssen, Roche, Celgene, Consultant: Roche and Celgene; GS: Honoraria: Novartis Pharmaceuticals Corporation, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Gilead, Kite, Merck, Servier, Morphosys, Roche, Grants: Roche; KB: Honoraria: Takeda, Roche, Gilead, Advisory Board: Takeda, Roche; MM: Travel grants: Gilead, Roche, Abbvie, Advisory board: Abbvie, Takeda; PF: Honoraria: Gilead, Roche, Abbvie, Janssen, Consultant: Janssen, Gilead; SLG: Honoraria: Roche, Janssen, Celgene, Servier, Gilead, Advisory board: Roche, Janssen, Celgene, Research funding: Roche, Janssen, Celgene; HT: Honoraria: Celgene, Roche, Karyopharm, Astra-Zeneca, Bristol-Myers Squibb, Grants: Celgene; ROC: Honoraria: Celgene, Abbvie, Janssen, Consultant: Roche, Takeda, Merck, BMS, Research funding: Roche, Gilead; MA: Advisory Board: Celgene, Grants: Celgene, Roche; CB: Advisory board: Roche and Janssen; CA: Advisory Board: Roche, Celgene, Takeda, Janssen, Amgen, Kite/Gilead; ENV: Consultant: Janssen, Keocyt et Sanofi; FM: Advisory Board: Roche, Celgene, Janssen, BMS, Gilead, Consultant: Epizyme, Gilead. All the remaining authors declare that they have no conflict of interest.
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Houot, R., Cartron, G., Bijou, F. et al. Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study. Leukemia 33, 776–780 (2019). https://doi.org/10.1038/s41375-018-0282-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-018-0282-y
This article is cited by
-
Comparison of the International Workshop Criteria and the Response Evaluation Criteria in Solid Tumors for indolent B-cell lymphoma
International Journal of Clinical Oncology (2021)
-
The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma
Investigational New Drugs (2019)